Cancer Partners of Nebraska offers unique access to clinical trials, thanks to our membership in two major National Cancer Institute (NCI) research networks: Alliance, as an MD Anderson Cancer Center affiliate, and ECOG-ACRIN Cancer Research Group.
If you are not able to resolve your concerns with the study doctor or study staff, if you have a complaint, or if you have general questions about what it means to be in a research study, you can call the Cancer Partners of Nebraska Human Research Protection Program at (402) 420-7000, Ext. 202, or email HumanProtections@cancerpartners.com.
Most clinical trials at Cancer Partners are interventional studies, meaning patients are assigned to a treatment or other intervention and their outcomes are measured. See the full list below sorted by type of cancer. If you wish to discuss a specific trial, please discuss it with your oncologist or contact our Research Department at (402) 327-7363.
HER2-, pT1N0M0, Oncotype ≤18 – A PHASE III CLINICAL TRIAL EVALUATING DEESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE ≤ 18 BREAST CANCER
Learn MoreA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF OP-1250 MONOTHERAPY VS STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST CANCER FOLLOWING ENDOCRINE AND CDK 4/6 INHIBITOR THERAPY (OPERA-01)
High Risk, Stage II-III, ER+, HER2- A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for High residual risk, Stage II-III, ER +, HER2
High Risk, Early Stage, TNBC – A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low positive/HER2-negative Breast Cancer
Pathology must remain blinded to treatment drugs.
Stage II-III, HER2+ BC
OPENING in late Nov 2025 – A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating Zanidatamab in combination with chemotherapy in participants with HER-2 positive breast cancer.
GBM, Expanded access to Gallium Maltolate (GAM)
Learn MoreCOLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-NORTH AMERICA)
Learn MoreRandomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Learn MoreIntegration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO (ACCIO)
Learn MoreAn open-label, randomized, controlled phase 3 study of sigvotatug vedotin in combination with pembrolizumab compared with pembrolizumab monotherapy as first-line treatment in participants with PD-L1 high (≥50% of tumor cells expressing PD-L1), locally advanced, unresectable, or metastatic non-small cell lung cancer.
MRI brain surveillance alone versus MRI surveillance and prophylactic cranial irradiation (PCI): a randomized phase III trial in small-cell lung cancer (Maverick)
AstraZeneca TROPION-Lung17 – A Phase III, Randomized, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)
This phase III trial studies whether adding apalutamide to the usual treatment improves outcomes in patients with lymph node-positive prostate cancer after surgery.
Learn MoreMAPK Pathway Altered Malignancies – Expanded Ulixertinib (BVD-523) access in Patients with Advanced MAPK Pathway-Altered Malignancies.
The list of available biomarker studies is always changing (blood, urine or bone marrow aspirate). Please contact Cancer Partners Research Department for the most current list.
$25 Gift Card for Participation
Age 30-85, Stage III-IV or recurrent, treatment naïve, active disease, no prior other cancers, no hx organ transplant
Age 35-80, Stage I-IV, treatment naïve, active disease, no long-acting anesthesia in past 60D, no hx organ transplant.
Stage IV or recurrent, treatment naïve (IV at Dx), no prior cancers w/in 5 yrs.
Basic Inclusion/Exclusion: please reach out if potential, research will review.
Stage IV or recurrent, no prior cancers w/in 5 years
Stage III-IV, treatment naïve or recurrent/relapsed/progressed at time of starting new tx, no other cancers.
